Previous close | 0.0025 |
Open | 0.0004 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0004 - 0.0004 |
52-week range | 0.0004 - 0.0570 |
Volume | |
Avg. volume | 317 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
Shares of biotechnology company Biophytis surged 73% to $1.59 on Monday following the announcement of a partnership deal with French pharmaceutical firm Skyepharma. The collaboration is set to produce regulatory batches of Sarconeos, a potential treatment for severe Covid-19 cases, in preparation for submitting marketing authorization applications.